Last $15.39 USD
Change Today -0.31 / -1.97%
Volume 1.9M
HALO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

halozyme therapeutics inc (HALO) Key Developments

Halozyme Therapeutics, Inc. Reports Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Revenue Guidance for the Year 2015

Halozyme Therapeutics, Inc. reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenues of $30,377,000 compared to $12,498,000 for the same period a year ago. Operating loss was $3,851,000 compared to $21,324,000 last year. Net loss was $5,274,000 or $0.04 per basic and diluted share compared to $21,987,000 or $0.19 per basic and diluted share last year. For the year, the company reported total revenues of $75,334,000 compared to $54,799,000 for the same period a year ago. Operating loss was $63,036,000 compared to $80,434,000 last year. Net loss was $68,375,000 or $0.56 per basic and diluted share compared to $83,479,000 or $0.74 per basic and diluted share last year. Net cash used for the year was approximately $44 million. For the year 2015, the company expects net revenues to be in the range of $85 million to $95 million.

Halozyme Therapeutics, Inc. to Report Q4, 2014 Results on Mar 02, 2015

Halozyme Therapeutics, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Mar 02, 2015

Halozyme Therapeutics, Inc., Q4 2014 Earnings Call, Mar 02, 2015

Halozyme Therapeutics, Inc., Q4 2014 Earnings Call, Mar 02, 2015

Halozyme Therapeutics, Inc. and Halozyme, Inc. Enter into Amended and Restated Loan and Security Agreement with Oxford Finance LLC and Silicon Valley Bank

On January 23, 2015, Halozyme Therapeutics, Inc. and its subsidiary Halozyme, Inc. entered into the Second Amendment to Amended and Restated Loan and Security Agreement And First Amendment to Disbursement Letter with Oxford Finance LLC and Silicon Valley Bank amending and restating the loan payment schedules of the Amended and Restated Loan and Security Agreement. The amended and restated term loan repayment schedule provides for interest only payments through January 2016, followed by consecutive equal monthly payments of principal and interest in arrears starting in February 2016 and continuing through the previously established maturity date of January 2018.

Halozyme Therapeutics, Inc. Appoints Jean-Pierre Bizzari, M.D. to its Board of Directors

Halozyme Therapeutics, Inc. announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors. Dr. Bizzari was Group Head, Clinical Oncology Development at Celgene Corporation, a role he held since 2008. In addition, he was Chairman of Celgene's hematology oncology development committee and a member of the company's management committee. Dr. Bizzari is a member of the Scientific Advisory Board of France'sNational Cancer Institute and is a board member of Transgene.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HALO:US $15.39 USD -0.31

HALO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amphastar Pharmaceuticals Inc $14.50 USD +0.01
View Industry Companies
 

Industry Analysis

HALO

Industry Average

Valuation HALO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 25.9x
Price/Book 47.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HALOZYME THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.